echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > In 2019, sales of these three drugs exceeded $10 billion.

    In 2019, sales of these three drugs exceeded $10 billion.

    • Last Update: 2020-08-06
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Pharmaceutical Network Industry News, Evaluate Pharma has released a list of the top 20 global drug sales in 2019.
    in terms of sales, more than $10 billion in sales accounted for three of the drug seats, namely, Humira in AbbVie, Keytruda in Mershadon and Revlimid of BMS.
    Humira is known as the world's "drug king", and indications are autoimmune diseases.
    the drug remains at the top of the global drug sales list in 2019.
    AbbVie's net income for 2019 totaled $33.266 billion, up 1.6 percent from a year earlier, while Humira generated $19.73 billion in sales for the company in 2019, down 3.8 percent from 2018.
    but Humira is facing the challenge of biosimilars.
    in the international market, in early April 2019, It was reported that AbbVie had responded to a 89% price cut by Humira in the European market.
    the industry believes it can be reflected in performance, humira's revenue in the U.S. market was $14.864 billion, still up 8.6 percent.
    but the international market revenue is 4.305 billion U.S. dollars, a sharp decline of 31.1%, while in the Chinese market, Humira is facing the impact of the listing of two domestic Adamu single anti-drug similar drugs, Aotai, Haizheng Pharmaceuticals, after a new round of health insurance negotiations began, Humira also began to take a low-cost route in the Chinese market, the price from 7200 yuan / branch to 1290 yuan / branch. According to
    , the impact of generics could reduce Humira's sales to $6.83 billion by 2026.
    in the PD-1 oncology immunotherapy field, Keytruda is the leader, has approved melanoma, NSCLC, bladder cancer, head and neck cancer, colorectal cancer and more than 20 therapeutic adaptations, global sales reached $11.12 billion in 2019, up 58% from the previous year, due to the introduction of a large number of new products.
    in the Chinese market, Keytruda has been approved for the treatment of esophageal squamous cell carcinoma (ESCC).
    With this new approval, Keytruda is now approved in China for five indications for three different types of cancer, including first-line treatment (single drug therapy and combined chemotherapy) for patients with advanced non-small cell lung cancer (NSCLC) and second-line treatment as advanced melanoma.
    , according to Evaluate Pharma, Keytruda will be approved for more indications by 2020.
    by 2026, Keytruda's sales could reach $24.91 billion.
    Revlimid is an immunomodulator, and the variety has been approved for a variety of indications, which vary from country to country, including multiple myeloma (MM), myeloding abnormal syndrome (MDS), cell lymphoma (MCL), follicular lymphoma (FL), limboma in the limbosis (MZL), etc.
    November 21, 2019, BMS paid $74 billion for New Base, putting the multiple myeloma heavyweight Revlimid in its pocket.
    Revlimid generated $11.11 billion in sales in 2019.
    , but the industry believes Evaluate does not forecast sales in 2026, but there are only two other biologics on the market, and the lack of generic challengers and the species will continue to grow in sales over the next few years.
    in addition to these three billion-dollar drugs, BMS's Opdivo, Regenerative Yuan/Bayer's Eylea, BMS/Pfizer's Eliquis also performed well.
    Opdivo has a place in immuno-oncology.
    2019, Opdivo's sales reached $8.06 billion.
    is understood to be linked to a series of new indications between Opdivo and BMS's Yervoy, a joint strategy that is likely to continue to boost overall sales over the next few years.
    According to Evaluate Pharma's estimates, Opdivo's sales are expected to grow by 5% per year by 2026, with sales expected to be $11.62 billion by 2026.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.